ACXP Acurx Pharmaceuticals, Inc.
Financings ·
Acurx agreed to sell 816,068 shares at $3.03 and pre-funded warrants for 9,017 shares, plus Series H warrants at $2.78 in a concurrent private placement. H.C. Wainwright & Co., LLC is the placement agent, and the 10-K says existing resources will not fund operations for at least 12 months.
Acurx Pharmaceuticals received a Nasdaq letter saying it no longer meets the $2,500,000 stockholders' equity minimum for the Capital Market. The company must submit a plan to regain compliance by May 9, 2025, and the notice rests on its 2024 annual report.
Acurx Pharmaceuticals sold 2,150,000 shares and pre-funded warrants for 595,000 more at about $0.40 each, and added private warrants for up to 8,235,000 shares. The price is far below the $1.015 the company got in a January offering, and a Nasdaq bid-price notice arrived on February 24, 2025.
Acurx will sell 2,463,058 shares at $1.015 to institutional investors and six insiders, with Series E warrants for the same number of shares at $0.90. H.C. Wainwright & Co. is the exclusive placement agent, and it receives a 7.0% cash fee plus a 1.0% management fee.
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Its candidates have a Gram-positive selective spectrum and block DNA polymerase IIIC (pol IIIC), an enzyme that is the primary catalyst for DNA replication in several Gram-positive bacteria. Its lead antibiotic candidate, ibezapolstat, targets Clostridioides difficile infection. The company says Phase 2 clinical data validated the efficacy of ibezapolstat and of pol IIIC as an antibacterial target, and that it is ready to enter Phase 3 trials. It expects to partner with a fully integrated pharmaceutical company for late-stage trials and commercialization. Its early-stage pipeline includes ACX-375C, a potential oral and parenteral treatment for Gram-positive bacteria including MRSA and VRE, which has proof of concept in animal studies. The pipeline also targets drug-resistant Streptococcus pneumoniae and B. anthracis. The company describes these pathogens as priority pathogens listed by the WHO, the CDC and the FDA. It states it has no commitments from potential partners or others to provide capital, and it continues to evaluate potential strategic transactions.
| Product or program | What it is | Stage |
|---|---|---|
| Ibezapolstat | Oral pol IIIC inhibitor antibiotic for Clostridioides difficile infection | Phase 2 completed; ready to enter Phase 3 |
| ACX-375C | Potential oral and parenteral antibiotic for Gram-positive bacteria including MRSA and VRE | early-stage; proof of concept in animal studies |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $1.8 million | $5.4 million |
| Net income (loss) | -$8.0 million | -$14.1 million |
| Cash from operations | -$6.8 million | -$10.4 million |
| Cash and equivalents | $7.6 million | $3.7 million |
Our latest story on this, dated Apr 16, 2026: "Acurx Pharmaceuticals prices $2.5 million registered direct offering with warrants". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 28, 2025: "Acurx Pharmaceuticals gets Nasdaq stockholders' equity deficiency notice". The story links the filing or release it is based on. Read the story.
Acurx Pharmaceuticals, Inc. trades under the ticker ACXP on NASDAQ.
Acurx Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Acurx Pharmaceuticals, Inc. is 1736243. Its filings are on SEC EDGAR.
5,269,921 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Acurx Pharmaceuticals, Inc. under United States.
Our directory classifies Acurx Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Acurx Pharmaceuticals, Inc. is US00510M2035.
aibio.space lists Acurx Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Its candidates have a Gram-positive selective spectrum and block DNA polymerase IIIC (pol IIIC), an enzyme that is the primary catalyst for DNA replication in several Gram-positive bacteria.
Ibezapolstat: Oral pol IIIC inhibitor antibiotic for Clostridioides difficile infection Stage: Phase 2 completed; ready to enter Phase 3.
ACX-375C: Potential oral and parenteral antibiotic for Gram-positive bacteria including MRSA and VRE Stage: early-stage; proof of concept in animal studies.
Acurx Pharmaceuticals, Inc. reported a net loss of $8.0 million for the fiscal year ended Dec 31, 2025, and used $6.8 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 424B5. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio